Drug of Abuse (DOA) Testing Market by Product Type and End User - Global Industry Analysis & Forecast to 2027
Published On : September 2019 Pages : 160 Category: Pharma & Healthcare Report Code : HC095880
Drug of Abuse (DOA) Testing Market by Product Type (Immunoassay Analyzers, Breath Analyzers, Chromatography Instruments, Assay Kits & Reagents, Others) End User (Hospitals, Diagnostic laboratories, On-the-spot Testing, Forensic Laboratories, Others) - Global Industry Analysis & Forecast to 2027
Industry Outlook and Trend Analysis
The drug of abuse (DOA) testing market has encountered significant development over the recent years and is anticipated to grow tremendously over the forecast period. Drugs of abuse testing is the detection of at least one illicit and additionally endorsed substances in the urine, blood, saliva, hair, or sweat. Testing identifies substances not typically found in the body, except for certain hormones and steroids estimated as a feature of sports testing.
Drivers and Restraints
Top-down and bottom-up approaches are used to validate the global drug of abuse (DOA) testing market size market and estimate the market size for company, regions segments, type segments and applications (end users). In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub segments listed in this report. Extensive qualitative and further quantitative analysis is also done from all the numbers arrived at in the complete market engineering process to list key information throughout the report.
Regional Insights
The data for 2021 is an estimate, based on the history data and the integrated view of industry experts, manufacturers, distributors and end users etc.
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Southeast Asia
- Rest of Asia-Pacific
- South America
- Brazil
- Argentina
- Columbia
- Rest of South America
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Nigeria
- South Africa
- Rest of MEA
Competitive Analysis
The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and share of the overall industry.
- Danaher Corporation
- ThermoFisher Scientific Inc.
- Laboratory Corporation of America Holdings
- Siemens AG
- Bio-Rad Laboratories, Inc.
- Merck KGaA
- Abbott Laboratories
- Waters Corporation
- Quest Diagnostics Inc.
- F. Hoffmann-La Roche AG
Some of the key questions answered by the report are:
- What was the market size in 2017 and forecast from 2017 to 2027?
- What will be the industry market growth from 2017 to 2027?
- What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
- What are the major segments leading the market growth and why?
- Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?
Market Classification
o Drug of Abuse (DOA) Testing Market, By Product Type, Estimates and Forecast, 2017-2027 ($Million)
o Immunoassay Analyzers
o Breath Analyzers
o Chromatography Instruments
o Assay Kits & Reagents
o Others
o Drug of Abuse (DOA) Testing Market, By End User, Estimates and Forecast, 2017-2027 ($Million)
o Hospitals
o Diagnostic laboratories
o On-the-spot Testing
o Forensic Laboratories
o Others
o Drug of Abuse (DOA) Testing Market, By Key Players, Estimates and Forecast, 2017-2027 ($Million)
o Danaher Corporation
o ThermoFisher Scientific Inc.
o Laboratory Corporation of America Holdings
o Siemens AG
o Bio-Rad Laboratories, Inc.
o Merck KGaA
o Abbott Laboratories
o Waters Corporation
o Quest Diagnostics Inc.
o F. Hoffmann-La Roche AG
o Drug of Abuse (DOA) Testing Market, By Region, Estimates and Forecast, 2017-2027 ($Million)
o North America
§ North America Drug of Abuse (DOA) Testing Market , By Country
o U.S. Drug of Abuse (DOA) Testing Market
o Canada Drug of Abuse (DOA) Testing Market
o Mexico Drug of Abuse (DOA) Testing Market
o Europe
§ Europe Drug of Abuse (DOA) Testing Market , By Country
o Germany Drug of Abuse (DOA) Testing Market
o UK Drug of Abuse (DOA) Testing Market
o France Drug of Abuse (DOA) Testing Market
o Russia Drug of Abuse (DOA) Testing Market
o Italy Drug of Abuse (DOA) Testing Market
o Rest of Europe Drug of Abuse (DOA) Testing Market
o Asia-Pacific
§ Asia-Pacific Drug of Abuse (DOA) Testing Market , By Country
o China Drug of Abuse (DOA) Testing Market
o Japan Drug of Abuse (DOA) Testing Market
o South Korea Drug of Abuse (DOA) Testing Market
o India Drug of Abuse (DOA) Testing Market
o Southeast Asia Drug of Abuse (DOA) Testing Market
o Rest of Asia-Pacific Drug of Abuse (DOA) Testing Market
o South America
§ South America Drug of Abuse (DOA) Testing Market , By Country
o Brazil Drug of Abuse (DOA) Testing Market
o Argentina Drug of Abuse (DOA) Testing Market
o Columbia Drug of Abuse (DOA) Testing Market
o Rest of South America Drug of Abuse (DOA) Testing Market
o Middle East and Africa
§ Middle East and Africa Drug of Abuse (DOA) Testing Market , By Country
o Saudi Arabia Drug of Abuse (DOA) Testing Market
o UAE Drug of Abuse (DOA) Testing Market
o Egypt Drug of Abuse (DOA) Testing Market
o Nigeria Drug of Abuse (DOA) Testing Market
o South Africa Drug of Abuse (DOA) Testing Market
o Rest of MEA Drug of Abuse (DOA) Testing Market
Table of Contents:
1. Introduction
1.1. Report Description
2. Executive Summary
2.1. Key Highlights
3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
4. Market Analysis by Regions
4.1. North America (United States, Canada and Mexico)
4.1.1. United States Market Status and Outlook (2017-2027)
4.1.2. Canada Market Status and Outlook (2017-2027)
4.1.3. Mexico Market Status and Outlook (2017-2027)
4.2. Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
4.2.1. Germany Market Status and Outlook (2017-2027)
4.2.2. France Market Status and Outlook (2017-2027)
4.2.3. UK Market Status and Outlook (2017-2027)
4.2.4. Russia Market Status and Outlook (2017-2027)
4.2.5. Italy Market Status and Outlook (2017-2027)
4.2.6. Rest of Europe Market Status and Outlook (2017-2027)
4.3. Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)
4.3.1. China Market Status and Outlook (2017-2027)
4.3.2. Japan Market Status and Outlook (2017-2027)
4.3.3. Korea Market Status and Outlook (2017-2027)
4.3.4. India Market Status and Outlook (2017-2027)
4.3.5. Southeast Asia Market Status and Outlook (2017-2027)
4.3.6. Rest of Asia-Pacific Market Status and Outlook (2017-2027)
4.4. South America (Brazil, Argentina, Columbia and Rest of South America)
4.4.1. Brazil Market Status and Outlook (2017-2027)
4.4.2. Argentina Market Status and Outlook (2017-2027)
4.4.3. Columbia Market Status and Outlook (2017-2027)
4.4.4. Rest of South America Market Status and Outlook (2017-2027)
4.5. Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)
4.5.1. Saudi Arabia Market Status and Outlook (2017-2027)
4.5.2. United Arab Emirates Market Status and Outlook (2017-2027)
4.5.3. Egypt Market Status and Outlook (2017-2027)
4.5.4. Nigeria Market Status and Outlook (2017-2027)
4.5.5. South Africa Market Status and Outlook (2017-2027)
4.5.6. Turkey Market Status and Outlook (2017-2027)
4.5.7. Rest of Middle East and Africa Market Status and Outlook (2017-2027)
5. Drug Of Abuse (DOA) Testing Market, By Product Type
5.1. Introduction
5.2. Global Drug Of Abuse (DOA) Testing Revenue and Market Share by Product Type (2017-2027)
5.2.1. Global Drug Of Abuse (DOA) Testing Revenue and Revenue Share by Product Type (2017-2027)
5.3. Immunoassay Analyzers
5.3.1. Global Immunoassay Analyzers Revenue and Growth Rate (2017-2027)
5.4. Breath Analyzers
5.4.1. Global Breath Analyzers Revenue and Growth Rate (2017-2027)
5.5. Chromatography Instruments
5.5.1. Global Chromatography Instruments Revenue and Growth Rate (2017-2027)
5.6. Assay Kits & Reagents
5.6.1. Global Assay Kits & Reagents Revenue and Growth Rate (2017-2027)
5.7. Others
5.7.1. Global Others Revenue and Growth Rate (2017-2027)
6. Drug Of Abuse (DOA) Testing Market, By End User
6.1. Introduction
6.2. Global Drug Of Abuse (DOA) Testing Revenue and Market Share by End User (2017-2027)
6.2.1. Global Drug Of Abuse (DOA) Testing Revenue and Revenue Share by End User (2017-2027)
6.3. Hospitals
6.3.1. Global Hospitals Revenue and Growth Rate (2017-2027)
6.4. Diagnostic laboratories
6.4.1. Global Diagnostic laboratories Revenue and Growth Rate (2017-2027)
6.5. On-the-spot Testing
6.5.1. Global On-the-spot Testing Revenue and Growth Rate (2017-2027)
6.6. Forensic Laboratories
6.6.1. Global Forensic Laboratories Revenue and Growth Rate (2017-2027)
6.7. Others
6.7.1. Global Others Revenue and Growth Rate (2017-2027)
7. Drug Of Abuse (DOA) Testing Market, By Region
7.1. Introduction
7.2. Global Drug Of Abuse (DOA) Testing Revenue and Market Share by Regions
7.2.1. Global Drug Of Abuse (DOA) Testing Revenue by Regions (2017-2027)
7.3. North America Drug Of Abuse (DOA) Testing by Countries
7.3.1. North America Drug Of Abuse (DOA) Testing Revenue and Growth Rate (2017-2027)
7.3.2. North America Drug Of Abuse (DOA) Testing Revenue (Million USD) by Countries (2017-2027)
7.3.3. United States
7.3.3.1. United States Drug Of Abuse (DOA) Testing Revenue (Millions USD) and Growth Rate (2017-2027)
7.3.4. Canada
7.3.4.1. Canada Drug Of Abuse (DOA) Testing Revenue (Millions USD) and Growth Rate (2017-2027)
7.3.5. Mexico
7.3.5.1. Mexico Drug Of Abuse (DOA) Testing Revenue (Millions USD) and Growth Rate (2017-2027)
7.4. Europe Drug Of Abuse (DOA) Testing by Countries
7.4.1. Europe Drug Of Abuse (DOA) Testing Revenue and Growth Rate (2017-2027)
7.4.2. Europe Drug Of Abuse (DOA) Testing Revenue (Million USD) by Countries (2017-2027)
7.4.3. Germany
7.4.3.1. Germany Drug Of Abuse (DOA) Testing Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.4. France
7.4.4.1. France Drug Of Abuse (DOA) Testing Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.5. UK
7.4.5.1. UK Drug Of Abuse (DOA) Testing Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.6. Russia
7.4.6.1. Russia Drug Of Abuse (DOA) Testing Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.7. Italy
7.4.7.1. Italy Drug Of Abuse (DOA) Testing Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.8. Rest of Europe
7.4.8.1. Rest of Europe Drug Of Abuse (DOA) Testing Revenue (Millions USD) and Growth Rate (2017-2027)
7.5. Asia-Pacific Drug Of Abuse (DOA) Testing by Countries
7.5.1. Asia-Pacific Drug Of Abuse (DOA) Testing Revenue and Growth Rate (2017-2027)
7.5.2. Asia-Pacific Drug Of Abuse (DOA) Testing Revenue (Million USD) by Countries (2017-2027)
7.5.3. China
7.5.3.1. China Drug Of Abuse (DOA) Testing Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.4. Japan
7.5.4.1. Japan Drug Of Abuse (DOA) Testing Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.5. Korea
7.5.5.1. Korea Drug Of Abuse (DOA) Testing Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.6. India
7.5.6.1. India Drug Of Abuse (DOA) Testing Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.7. Southeast Asia
7.5.7.1. Southeast Asia Drug Of Abuse (DOA) Testing Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.8. Rest of Asia-Pacific
7.5.8.1. Rest of Asia-Pacific Drug Of Abuse (DOA) Testing Revenue (Millions USD) and Growth Rate (2017-2027)
7.6. South America Drug Of Abuse (DOA) Testing by Countries
7.6.1. South America Drug Of Abuse (DOA) Testing Revenue and Growth Rate (2017-2027)
7.6.2. South America Drug Of Abuse (DOA) Testing Revenue (Million USD) by Countries (2017-2027)
7.6.3. Brazil
7.6.3.1. Brazil Drug Of Abuse (DOA) Testing Revenue (Millions USD) and Growth Rate (2017-2027)
7.6.4. Argentina
7.6.4.1. Argentina Drug Of Abuse (DOA) Testing Revenue (Millions USD) and Growth Rate (2017-2027)
7.6.5. Columbia
7.6.5.1. Columbia Drug Of Abuse (DOA) Testing Revenue (Millions USD) and Growth Rate (2017-2027)
7.6.6. Rest of South America
7.6.6.1. Rest of South America Drug Of Abuse (DOA) Testing Revenue (Millions USD) and Growth Rate (2017-2027)
7.7. Middle East and Africa Drug Of Abuse (DOA) Testing by Countries
7.7.1. Middle East and Africa Drug Of Abuse (DOA) Testing Revenue and Growth Rate (2017-2027)
7.7.2. Middle East and Africa Drug Of Abuse (DOA) Testing Revenue (Million USD) by Countries (2017-2027)
7.7.3. Saudi Arabia
7.7.3.1. Saudi Arabia Drug Of Abuse (DOA) Testing Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.4. United Arab Emirates
7.7.4.1. United Arab Emirates Drug Of Abuse (DOA) Testing Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.5. Egypt
7.7.5.1. Egypt Drug Of Abuse (DOA) Testing Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.6. Nigeria
7.7.6.1. Nigeria Drug Of Abuse (DOA) Testing Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.7. South Africa
7.7.7.1. South Africa Drug Of Abuse (DOA) Testing Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.8. Turkey
7.7.8.1. Turkey Drug Of Abuse (DOA) Testing Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.9. Rest of Middle East and Africa
7.7.9.1. Rest of Middle East and Africa Drug Of Abuse (DOA) Testing Revenue (Millions USD) and Growth Rate (2017-2027)
8. Company Profiles
8.1. Danaher Corporation
8.1.1. Business Overview
8.1.2. Service Portfolio
8.1.3. Strategic Developments
8.1.4. Financial Overview
8.2. ThermoFisher Scientific Inc.
8.2.1. Business Overview
8.2.2. Service Portfolio
8.2.3. Strategic Developments
8.2.4. Financial Overview
8.3. Laboratory Corporation of America Holdings
8.3.1. Business Overview
8.3.2. Service Portfolio
8.3.3. Strategic Developments
8.3.4. Financial Overview
8.4. Siemens AG
8.4.1. Business Overview
8.4.2. Service Portfolio
8.4.3. Strategic Developments
8.4.4. Financial Overview
8.5. Bio-Rad Laboratories, Inc.
8.5.1. Business Overview
8.5.2. Service Portfolio
8.5.3. Strategic Developments
8.5.4. Financial Overview
8.6. Merck KGaA
8.6.1. Business Overview
8.6.2. Service Portfolio
8.6.3. Strategic Developments
8.6.4. Financial Overview
8.7. Abbott Laboratories
8.7.1. Business Overview
8.7.2. Service Portfolio
8.7.3. Strategic Developments
8.7.4. Financial Overview
8.8. Waters Corporation
8.8.1. Business Overview
8.8.2. Service Portfolio
8.8.3. Strategic Developments
8.8.4. Financial Overview
8.9. Quest Diagnostics Inc.
8.9.1. Business Overview
8.9.2. Service Portfolio
8.9.3. Strategic Developments
8.9.4. Financial Overview
8.10. F. Hoffmann-La Roche AG
8.10.1. Business Overview
8.10.2. Service Portfolio
8.10.3. Strategic Developments
8.10.4. Financial Overview
9. Drug Of Abuse (DOA) Testing Market Forecast (2017-2027)
9.1. Global Drug Of Abuse (DOA) Testing Revenue (Millions USD) and Growth Rate (2017-2027)
9.2. Drug Of Abuse (DOA) Testing Market Forecast by Regions (2017-2027)
9.2.1. North America Drug Of Abuse (DOA) Testing Market Forecast (2017-2027)
9.2.1.1. United States Drug Of Abuse (DOA) Testing Market Forecast (2017-2027)
9.2.1.2. Canada Drug Of Abuse (DOA) Testing Market Forecast (2017-2027)
9.2.1.3. Mexico Drug Of Abuse (DOA) Testing Market Forecast (2017-2027)
9.2.2. Europe Drug Of Abuse (DOA) Testing Market Forecast (2017-2027)
9.2.2.1. Germany Drug Of Abuse (DOA) Testing Market Forecast (2017-2027)
9.2.2.2. France Drug Of Abuse (DOA) Testing Market Forecast (2017-2027)
9.2.2.3. UK Drug Of Abuse (DOA) Testing Market Forecast (2017-2027)
9.2.2.4. Russia Drug Of Abuse (DOA) Testing Market Forecast (2017-2027)
9.2.2.5. Italy Drug Of Abuse (DOA) Testing Market Forecast (2017-2027)
9.2.2.6. Rest of Europe Drug Of Abuse (DOA) Testing Market Forecast (2017-2027)
9.2.3. Asia-Pacific Drug Of Abuse (DOA) Testing Market Forecast (2017-2027)
9.2.3.1. China Drug Of Abuse (DOA) Testing Market Forecast (2017-2027)
9.2.3.2. Japan Drug Of Abuse (DOA) Testing Market Forecast (2017-2027)
9.2.3.3. Korea Drug Of Abuse (DOA) Testing Market Forecast (2017-2027)
9.2.3.4. India Drug Of Abuse (DOA) Testing Market Forecast (2017-2027)
9.2.3.5. Southeast Asia Drug Of Abuse (DOA) Testing Market Forecast (2017-2027)
9.2.3.6. Rest of Asia-Pacific Drug Of Abuse (DOA) Testing Market Forecast (2017-2027)
9.2.4. South America Drug Of Abuse (DOA) Testing Market Forecast (2017-2027)
9.2.4.1. Brazil Drug Of Abuse (DOA) Testing Market Forecast (2017-2027)
9.2.4.2. Argentina Drug Of Abuse (DOA) Testing Market Forecast (2017-2027)
9.2.4.3. Columbia Drug Of Abuse (DOA) Testing Market Forecast (2017-2027)
9.2.4.4. Rest of South America Drug Of Abuse (DOA) Testing Market Forecast (2017-2027)
9.2.5. Middle East and Africa Drug Of Abuse (DOA) Testing Market Forecast (2017-2027)
9.2.5.1. Saudi Arabia Drug Of Abuse (DOA) Testing Market Forecast (2017-2027)
9.2.5.2. United Arab Emirates Drug Of Abuse (DOA) Testing Market Forecast (2017-2027)
9.2.5.3. Egypt Drug Of Abuse (DOA) Testing Market Forecast (2017-2027)
9.2.5.4. Nigeria Drug Of Abuse (DOA) Testing Market Forecast (2017-2027)
9.2.5.5. South Africa Drug Of Abuse (DOA) Testing Market Forecast (2017-2027)
9.2.5.6. Turkey Drug Of Abuse (DOA) Testing Market Forecast (2017-2027)
9.2.5.7. Rest of Middle East and Africa Drug Of Abuse (DOA) Testing Market Forecast (2017-2027)
9.3. Drug Of Abuse (DOA) Testing Market Forecast by Product Type (2017-2027)
9.3.1. Drug Of Abuse (DOA) Testing Forecast by Product Type (2017-2027)
9.3.2. Drug Of Abuse (DOA) Testing Market Share Forecast by Product Type (2017-2027)
9.4. Drug Of Abuse (DOA) Testing Market Forecast by End User (2017-2027)
9.4.1. Drug Of Abuse (DOA) Testing Forecast by End User (2017-2027)
9.4.2. Drug Of Abuse (DOA) Testing Market Share Forecast by End User (2017-2027)
List of Tables
List of Tables and Figures:
Figure United States Drug Of Abuse (DOA) Testing Revenue (Million USD) and Growth Rate (2017-2025)
Figure Canada Drug Of Abuse (DOA) Testing Revenue (Million USD) and Growth Rate (2017-2025)
Figure Mexico Drug Of Abuse (DOA) Testing Revenue (Million USD) and Growth Rate (2017-2025)
Figure Germany Drug Of Abuse (DOA) Testing Revenue (Million USD) and Growth Rate (2017-2025)
Figure France Drug Of Abuse (DOA) Testing Revenue (Million USD) and Growth Rate (2017-2025)
Figure UK Drug Of Abuse (DOA) Testing Revenue (Million USD) and Growth Rate (2017-2025)
Figure Russia Drug Of Abuse (DOA) Testing Revenue (Million USD) and Growth Rate (2017-2025)
Figure Italy Drug Of Abuse (DOA) Testing Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Europe Drug Of Abuse (DOA) Testing Revenue (Million USD) and Growth Rate (2017-2025)
Figure China Drug Of Abuse (DOA) Testing Revenue (Million USD) and Growth Rate (2017-2025)
Figure Japan Drug Of Abuse (DOA) Testing Revenue (Million USD) and Growth Rate (2017-2025)
Figure Korea Drug Of Abuse (DOA) Testing Revenue (Million USD) and Growth Rate (2017-2025)
Figure India Drug Of Abuse (DOA) Testing Revenue (Million USD) and Growth Rate (2017-2025)
Figure Southeast Asia Drug Of Abuse (DOA) Testing Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Asia-Pacific Drug Of Abuse (DOA) Testing Revenue (Million USD) and Growth Rate (2017-2025)
Figure Brazil Drug Of Abuse (DOA) Testing Revenue (Million USD) and Growth Rate (2017-2025)
Figure Argentina Drug Of Abuse (DOA) Testing Revenue (Million USD) and Growth Rate (2017-2025)
Figure Columbia Drug Of Abuse (DOA) Testing Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of South America Drug Of Abuse (DOA) Testing Revenue (Million USD) and Growth Rate (2017-2025)
Figure Saudi Arabia Drug Of Abuse (DOA) Testing Revenue (Million USD) and Growth Rate (2017-2025)
Figure United Arab Emirates Drug Of Abuse (DOA) Testing Revenue (Million USD) and Growth Rate (2017-2025)
Figure Egypt Drug Of Abuse (DOA) Testing Revenue (Million USD) and Growth Rate (2017-2025)
Figure Nigeria Drug Of Abuse (DOA) Testing Revenue (Million USD) and Growth Rate (2017-2025)
Figure South Africa Drug Of Abuse (DOA) Testing Revenue (Million USD) and Growth Rate (2017-2025)
Figure Turkey Drug Of Abuse (DOA) Testing Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Middle East and Africa Drug Of Abuse (DOA) Testing Revenue (Million USD) and Growth Rate (2017-2025)
Table Global Drug Of Abuse (DOA) Testing Revenue and Revenue Share by Product Type (2017-2018)
Figure Global Immunoassay Analyzers Revenue and Growth Rate (2017-2018)
Figure Global Breath Analyzers Revenue and Growth Rate (2017-2018)
Figure Global Chromatography Instruments Revenue and Growth Rate (2017-2018)
Figure Global Assay Kits & Reagents Revenue and Growth Rate (2017-2018)
Figure Global Others Revenue and Growth Rate (2017-2018)
Table Global Drug Of Abuse (DOA) Testing Revenue and Revenue Share by End User (2017-2018)
Figure Global Hospitals Revenue and Growth Rate (2017-2018)
Figure Global Diagnostic laboratories Revenue and Growth Rate (2017-2018)
Figure Global On-the-spot Testing Revenue and Growth Rate (2017-2018)
Figure Global Forensic Laboratories Revenue and Growth Rate (2017-2018)
Figure Global Others Revenue and Growth Rate (2017-2018)
Table Global Drug Of Abuse (DOA) Testing Revenue by Regions (2017-2018)
Figure North America Drug Of Abuse (DOA) Testing Growth Rate (2017-2018)
Figure North America Drug Of Abuse (DOA) Testing Revenue and Growth Rate (2017-2018)
Figure North America Drug Of Abuse (DOA) Testing by Countries (2017-2018)
Figure North America Drug Of Abuse (DOA) Testing Revenue (Million USD) by Countries (2017-2018)
Figure United States Drug Of Abuse (DOA) Testing Growth Rate (2017-2018)
Figure United States Drug Of Abuse (DOA) Testing Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Canada Drug Of Abuse (DOA) Testing Growth Rate (2017-2018)
Figure Canada Drug Of Abuse (DOA) Testing Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Mexico Drug Of Abuse (DOA) Testing Growth Rate (2017-2018)
Figure Mexico Drug Of Abuse (DOA) Testing Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Europe Drug Of Abuse (DOA) Testing Growth Rate (2017-2018)
Figure Europe Drug Of Abuse (DOA) Testing Revenue and Growth Rate (2017-2018)
Figure Europe Drug Of Abuse (DOA) Testing by Countries (2017-2018)
Figure Europe Drug Of Abuse (DOA) Testing Revenue (Million USD) by Countries (2017-2018)
Figure Germany Drug Of Abuse (DOA) Testing Growth Rate (2017-2018)
Figure Germany Drug Of Abuse (DOA) Testing Revenue (Millions USD) and Growth Rate (2017-2018)
Figure France Drug Of Abuse (DOA) Testing Growth Rate (2017-2018)
Figure France Drug Of Abuse (DOA) Testing Revenue (Millions USD) and Growth Rate (2017-2018)
Figure UK Drug Of Abuse (DOA) Testing Growth Rate (2017-2018)
Figure UK Drug Of Abuse (DOA) Testing Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Russia Drug Of Abuse (DOA) Testing Growth Rate (2017-2018)
Figure Russia Drug Of Abuse (DOA) Testing Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Italy Drug Of Abuse (DOA) Testing Growth Rate (2017-2018)
Figure Italy Drug Of Abuse (DOA) Testing Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Europe Drug Of Abuse (DOA) Testing Growth Rate (2017-2018)
Figure Rest of Europe Drug Of Abuse (DOA) Testing Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Asia-Pacific Drug Of Abuse (DOA) Testing Growth Rate (2017-2018)
Figure Asia-Pacific Drug Of Abuse (DOA) Testing Revenue and Growth Rate (2017-2018)
Figure Asia-Pacific Drug Of Abuse (DOA) Testing by Countries (2017-2018)
Figure Asia-Pacific Drug Of Abuse (DOA) Testing Revenue (Million USD) by Countries (2017-2018)
Figure China Drug Of Abuse (DOA) Testing Growth Rate (2017-2018)
Figure China Drug Of Abuse (DOA) Testing Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Japan Drug Of Abuse (DOA) Testing Growth Rate (2017-2018)
Figure Japan Drug Of Abuse (DOA) Testing Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Korea Drug Of Abuse (DOA) Testing Growth Rate (2017-2018)
Figure Korea Drug Of Abuse (DOA) Testing Revenue (Millions USD) and Growth Rate (2017-2018)
Figure India Drug Of Abuse (DOA) Testing Growth Rate (2017-2018)
Figure India Drug Of Abuse (DOA) Testing Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Southeast Asia Drug Of Abuse (DOA) Testing Growth Rate (2017-2018)
Figure Southeast Asia Drug Of Abuse (DOA) Testing Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Drug Of Abuse (DOA) Testing Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Drug Of Abuse (DOA) Testing Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South America Drug Of Abuse (DOA) Testing Growth Rate (2017-2018)
Figure South America Drug Of Abuse (DOA) Testing Revenue and Growth Rate (2017-2018)
Figure South America Drug Of Abuse (DOA) Testing by Countries (2017-2018)
Figure South America Drug Of Abuse (DOA) Testing Revenue (Million USD) by Countries (2017-2018)
Figure Brazil Drug Of Abuse (DOA) Testing Growth Rate (2017-2018)
Figure Brazil Drug Of Abuse (DOA) Testing Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Argentina Drug Of Abuse (DOA) Testing Growth Rate (2017-2018)
Figure Argentina Drug Of Abuse (DOA) Testing Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Columbia Drug Of Abuse (DOA) Testing Growth Rate (2017-2018)
Figure Columbia Drug Of Abuse (DOA) Testing Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of South America Drug Of Abuse (DOA) Testing Growth Rate (2017-2018)
Figure Rest of South America Drug Of Abuse (DOA) Testing Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Middle East and Africa Drug Of Abuse (DOA) Testing Growth Rate (2017-2018)
Figure Middle East and Africa Drug Of Abuse (DOA) Testing Revenue and Growth Rate (2017-2018)
Figure Middle East and Africa Drug Of Abuse (DOA) Testing by Countries (2017-2018)
Figure Middle East and Africa Drug Of Abuse (DOA) Testing Revenue (Million USD) by Countries (2017-2018)
Figure Saudi Arabia Drug Of Abuse (DOA) Testing Growth Rate (2017-2018)
Figure Saudi Arabia Drug Of Abuse (DOA) Testing Revenue (Millions USD) and Growth Rate (2017-2018)
Figure United Arab Emirates Drug Of Abuse (DOA) Testing Growth Rate (2017-2018)
Figure United Arab Emirates Drug Of Abuse (DOA) Testing Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Egypt Drug Of Abuse (DOA) Testing Growth Rate (2017-2018)
Figure Egypt Drug Of Abuse (DOA) Testing Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Nigeria Drug Of Abuse (DOA) Testing Growth Rate (2017-2018)
Figure Nigeria Drug Of Abuse (DOA) Testing Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South Africa Drug Of Abuse (DOA) Testing Growth Rate (2017-2018)
Figure South Africa Drug Of Abuse (DOA) Testing Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Turkey Drug Of Abuse (DOA) Testing Growth Rate (2017-2018)
Figure Turkey Drug Of Abuse (DOA) Testing Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Drug Of Abuse (DOA) Testing Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Drug Of Abuse (DOA) Testing Revenue (Millions USD) and Growth Rate (2017-2018)
Table Danaher Corporation Drug Of Abuse (DOA) Testing Financial Overview
Table ThermoFisher Scientific Inc. Drug Of Abuse (DOA) Testing Financial Overview
Table Laboratory Corporation of America Holdings Drug Of Abuse (DOA) Testing Financial Overview
Table Siemens AG Drug Of Abuse (DOA) Testing Financial Overview
Table Bio-Rad Laboratories, Inc. Drug Of Abuse (DOA) Testing Financial Overview
Table Merck KGaA Drug Of Abuse (DOA) Testing Financial Overview
Table Abbott Laboratories Drug Of Abuse (DOA) Testing Financial Overview
Table Waters Corporation Drug Of Abuse (DOA) Testing Financial Overview
Table Quest Diagnostics Inc. Drug Of Abuse (DOA) Testing Financial Overview
Table F. Hoffmann-La Roche AG Drug Of Abuse (DOA) Testing Financial Overview
Figure Global Drug Of Abuse (DOA) Testing Revenue (Millions USD) and Growth Rate (2018-2025)
Table Drug Of Abuse (DOA) Testing Market Forecast by Regions (2018-2025)
Figure North America Drug Of Abuse (DOA) Testing Market Forecast (2018-2025)
Figure United States Drug Of Abuse (DOA) Testing Market Forecast (2018-2025)
Figure Canada Drug Of Abuse (DOA) Testing Market Forecast (2018-2025)
Figure Mexico Drug Of Abuse (DOA) Testing Market Forecast (2018-2025)
Figure Europe Drug Of Abuse (DOA) Testing Market Forecast (2018-2025)
Figure Germany Drug Of Abuse (DOA) Testing Market Forecast (2018-2025)
Figure France Drug Of Abuse (DOA) Testing Market Forecast (2018-2025)
Figure UK Drug Of Abuse (DOA) Testing Market Forecast (2018-2025)
Figure Russia Drug Of Abuse (DOA) Testing Market Forecast (2018-2025)
Figure Italy Drug Of Abuse (DOA) Testing Market Forecast (2018-2025)
Figure Rest of Europe Drug Of Abuse (DOA) Testing Market Forecast (2018-2025)
Figure Asia-Pacific Drug Of Abuse (DOA) Testing Market Forecast (2018-2025)
Figure China Drug Of Abuse (DOA) Testing Market Forecast (2018-2025)
Figure Japan Drug Of Abuse (DOA) Testing Market Forecast (2018-2025)
Figure Korea Drug Of Abuse (DOA) Testing Market Forecast (2018-2025)
Figure India Drug Of Abuse (DOA) Testing Market Forecast (2018-2025)
Figure Southeast Asia Drug Of Abuse (DOA) Testing Market Forecast (2018-2025)
Figure Rest of Asia-Pacific Drug Of Abuse (DOA) Testing Market Forecast (2018-2025)
Figure South America Drug Of Abuse (DOA) Testing Market Forecast (2018-2025)
Figure Brazil Drug Of Abuse (DOA) Testing Market Forecast (2018-2025)
Figure Argentina Drug Of Abuse (DOA) Testing Market Forecast (2018-2025)
Figure Columbia Drug Of Abuse (DOA) Testing Market Forecast (2018-2025)
Figure Rest of South America Drug Of Abuse (DOA) Testing Market Forecast (2018-2025)
Figure Middle East and Africa Drug Of Abuse (DOA) Testing Market Forecast (2018-2025)
Figure Saudi Arabia Drug Of Abuse (DOA) Testing Market Forecast (2018-2025)
Figure United Arab Emirates Drug Of Abuse (DOA) Testing Market Forecast (2018-2025)
Figure Egypt Drug Of Abuse (DOA) Testing Market Forecast (2018-2025)
Figure Nigeria Drug Of Abuse (DOA) Testing Market Forecast (2018-2025)
Figure South Africa Drug Of Abuse (DOA) Testing Market Forecast (2018-2025)
Figure Turkey Drug Of Abuse (DOA) Testing Market Forecast (2018-2025)
Figure Rest of Middle East and Africa Drug Of Abuse (DOA) Testing Market Forecast (2018-2025)
Figure Global Drug Of Abuse (DOA) Testing Forecast by Product Type (2018-2025)
Figure Global Drug Of Abuse (DOA) Testing Market Share Forecast by Product Type (2018-2025)
Figure Global Drug Of Abuse (DOA) Testing Forecast by Product Type (2018-2025)
Figure Global Drug Of Abuse (DOA) Testing Forecast by End User (2018-2025)
Figure Global Drug Of Abuse (DOA) Testing Market Share Forecast by End User (2018-2025)
Figure Global Drug Of Abuse (DOA) Testing Forecast by End User (2018-2025)
Please Note: Data related to the Companies are subject to Availability.
Research Methodology
We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.
Data Mining
Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.
Data Collection Matrix
|
Data Collection Matrix |
Supply Side |
Demand Side |
|
Primary Data Sources |
|
|
|
Secondary Data Sources |
|
|
Market Modeling and Forecasting
We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.
- Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
- Number of patients for particular device or medical procedure and
- Repeated use of particular device depending on health and condition of patient
- Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.
We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.
Data Validation
We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.
Data Triangulation
Industry Analysis
|
Qualitative Data |
Quantitative Data (2017-2025) |
|
|